

Baran Sumer, M.D., is Associate Professor and Chief of the Division of Head and Neck Oncology in UT Southwestern Medical Center's [Department of Otolaryngology](#), where he has served on the faculty since 2007. A specialist in head and neck cancer surgery and reconstruction, Dr. Sumer is also Director of the Head and Neck Oncology Disease Oriented Team at the Simmons Comprehensive Cancer Center.

After receiving a B.A. at Rutgers University, Dr. Sumer earned his medical degree from Case Western Reserve University. He then completed an internship in general surgery, a residency in otolaryngology, and a fellowship in head and neck oncologic surgery with a focus on transoral laser surgery and microvascular reconstruction at the Washington University in St. Louis School of Medicine.

Dr. Sumer is on the clinical staff at the North Texas VA Medical Center, the Children's Medical Center of Dallas, UT Southwestern Medical Center, and Parkland Health & Hospital System, all in Dallas, Texas.

He has participated in a wide variety of research studies devoted to advancing diagnostic and therapeutic techniques and technologies for head and neck cancer such as fluorescent imaging, biosensing, photodynamic therapy, multimodal therapies, and oral cancer surgical reconstruction techniques.

He serves as a reviewer for several peer-reviewed journals, including *Nature Biomedical Engineering*, *Head and Neck*, *Laryngoscope*, *Experimental Biology and Medicine*, *International Journal of Otolaryngology*, *Otolaryngology-Head and Neck Surgery*, and is an editor for the *Annals of Surgical Oncology*.

Among numerous recognitions, honors, and awards, Dr. Sumer has been recognized as among the best otolaryngology physicians in North Texas by *D Magazine*, is the recipient of a Texas Instruments Corporate Award Research Gift, the Triological Society Francis Lederer FUSION Grant for Nanotechnology Research, and the SEBM Best Paper Award in the Alan MacDiarmid Interdisciplinary Research Society for Experimental Biology and Medicine. His funding includes several R01 and U01 awards from the National Institutes of Health (NIH) and the National Cancer Institute (NCI), as well as the Cancer Prevention and Research Institute of Texas (CPRIT), and biotechnology companies such as **OncoNano Medicine**.